Merck Sharp Dohme Drug Patent Portfolio
Merck Sharp Dohme owns 12 orange book drugs protected by 66 US patents with Crixivan having the least patent protection, holding only 2 patents. And Juvisync with maximum patent protection, holding 11 patents. Given below is the list of Merck Sharp Dohme's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9908845 | Aryl ethers and uses thereof | 05 Sep, 2034 | Active |
| US9969689 | Aryl ethers and uses thereof | 05 Sep, 2034 | Active |
| USRE49948 | Aryl ethers and uses thereof | 05 Sep, 2034 | Active |
| US10098892 | Solid dosage formulations of an orexin receptor antagonist | 29 May, 2033 | Active |
| US11980623 | Solid dosage formulations of an orexin receptor antagonist | 29 May, 2033 | Active |
| US10603384 | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative | 28 Feb, 2033 | Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
| US9023790 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | 04 Jul, 2031 | Active |
| US9358297 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | 24 Jun, 2031 | Active |
| US7951797 | Substituted diazepan orexin receptor antagonists | 20 Nov, 2029 | Active |
| US7754731 | Potassium salt of an HIV integrase inhibitor | 11 Sep, 2029 | Active |
| US10117951 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US7754731 | Potassium salt of an HIV integrase inhibitor | 11 Mar, 2029 | Active |
| USRE46791 | Substituted dihydroquinazolines | 18 Jan, 2029 | Active |
| US7772178 | Pharmaceutical formulations and methods of treatment using the same | 11 Nov, 2027 | Active |
| US8119602 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | 17 Mar, 2027 | Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | 11 Oct, 2026 | Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | 11 Apr, 2026 | Active |
| USRE43298 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | 22 Dec, 2024 | Expired |
| US7196086 | Substituted dihydroquinazolines | 22 May, 2024 | Expired |
| US8513255 | Substituted dihydroquinazolines | 22 May, 2024 | Expired |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 03 Apr, 2024 | Expired |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 03 Oct, 2023 | Expired |
| US6987108 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | 08 Sep, 2023 | Expired |
| US7820660 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 25 Apr, 2023 | Expired |
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Apr, 2023 | Expired |
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Apr, 2023 | Expired |
| US7786118 | Pharmaceutical formulations of antineoplastic agents | 21 Feb, 2023 | Expired |
| US8623868 | Processes of making and using pharmaceutical formulations of antineoplastic agents | 21 Feb, 2023 | Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jan, 2023 | Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jan, 2023 | Expired |
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Oct, 2022 | Expired |
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | 21 Oct, 2022 | Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jul, 2022 | Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | 26 Jul, 2022 | Expired |
| US8168637 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes | 26 Jun, 2022 | Expired |
| US6689761 | Combination therapy for HIV infection | 10 Feb, 2021 | Expired |
| US5661151 | Tetrahydrofuran antifungals | 19 Jul, 2019 | Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto | 02 Feb, 2019 | Expired |
| US6514520 | Stabilized antihistamine syrup | 01 Dec, 2018 | Expired |
| US6514520 | Stabilized antihistamine syrup | 01 Jun, 2018 | Expired |
| US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection | 21 Mar, 2018 | Expired |
| US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection | 21 Mar, 2018 | Expired |
| US6645961 | Dry granulation formulation for an HIV protease inhibitor | 04 Mar, 2018 | Expired |
| US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection | 21 Sep, 2017 | Expired |
| US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection | 21 Sep, 2017 | Expired |
| US6177074 | Polyethylene glycol modified interferon therapy | 01 May, 2017 | Expired |
| US6461605 | Continuous low-dose cytokine infusion therapy | 01 May, 2017 | Expired |
| US6524570 | Polyethylene glycol modified interferon therapy | 01 May, 2017 | Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals | 24 Apr, 2017 | Expired |
| US6177074 | Polyethylene glycol modified interferon therapy | 01 Nov, 2016 | Expired |
| US6461605 | Continuous low-dose cytokine infusion therapy | 01 Nov, 2016 | Expired |
| US6524570 | Polyethylene glycol modified interferon therapy | 01 Nov, 2016 | Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine | 30 Jun, 2015 | Expired |
| US7214683 | Compositions of descarboethoxyloratadine | 30 Jun, 2015 | Expired |
| US7214684 | Methods for the treatment of allergic rhinitis | 30 Jun, 2015 | Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine | 30 Dec, 2014 | Expired |
| US7214683 | Compositions of descarboethoxyloratadine | 30 Dec, 2014 | Expired |
| US7214684 | Methods for the treatment of allergic rhinitis | 30 Dec, 2014 | Expired |
| US5703079 | Tetrahydrofuran antifungals | 26 Aug, 2014 | Expired |
| US5260291 | Tetrazine derivatives | 11 Feb, 2014 | Expired |
| US5260291 | Tetrazine derivatives | 11 Aug, 2013 | Expired |
Latest Legal Activities on Merck Sharp Dohme's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Merck Sharp Dohme.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 03 Jun, 2024 | US8168637 |
|
Email Notification
Critical
| 01 May, 2024 | US10603384 |
|
Email Notification
Critical
| 30 Apr, 2024 | US10603384 |
| Patent eCofC Notification | 30 Apr, 2024 | US10603384 |
| Mail Patent eCofC Notification | 30 Apr, 2024 | US10603384 |
| Recordation of Patent eCertificate of Correction | 30 Apr, 2024 | US10603384 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
|
Maintenance Fee Reminder Mailed
Critical
| 29 Apr, 2024 | US8263600 |
| Court Processing Terminated | 17 Apr, 2024 | US7326708 (Litigated) |
| Court Processing Terminated | 17 Apr, 2024 | US7326708 (Litigated) |
| Post Issue Communication - Certificate of Correction | 10 Apr, 2024 | US10603384 |
|
Withdrawal of Application for PTE
Critical
| 07 Feb, 2024 | US8513255 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9908845 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9969689 |
| Election in Response to Notice of Final Determination | 27 Dec, 2023 | US8513255 |
Merck Sharp Dohme's Drug Patent Litigations
Merck Sharp Dohme's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 22, 2001, against patent number US6689761. The petitioner , challenged the validity of this patent, with CHODAKEWITZ et al as the respondent. Click below to track the latest information on how companies are challenging Merck Sharp Dohme's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7326708 | June, 2020 |
Final Written Decision
(10 May, 2021)
| Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US7326708 | June, 2020 |
Final Written Decision
(10 May, 2021)
| Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
| US7326708 | October, 2019 |
Final Written Decision
(07 May, 2021)
| Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
| US7326708 | June, 2020 |
Terminated-Settled
(08 Dec, 2020)
| Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7214683 | December, 2004 |
Decision
(24 Mar, 2005)
| ABERG et al | |
| US6645961 | June, 2001 |
Decision
(27 Mar, 2002)
| LUI et al | |
| US6689761 | March, 2001 |
Decision
(25 May, 2001)
| CHODAKEWITZ et al | |
Merck Sharp Dohme Drug Patents' Oppositions Filed in EPO
Merck Sharp Dohme drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 11, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04755691A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP18171672A | May, 2022 | Ethypharm | Granted and Under Opposition |
| EP18171672A | May, 2022 | Fresenius Kabi Deutschland GmbH | Granted and Under Opposition |
| EP18171672A | May, 2022 | Aera A/S | Granted and Under Opposition |
| EP18171672A | May, 2022 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP05077584A | Mar, 2011 | APOTEX INC. | Revoked |
| EP03709188A | Mar, 2009 | CHEMAGIS LTD. | Opposition rejected |
| EP04755691A | Jun, 2008 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
Merck Sharp Dohme's Family Patents
Merck Sharp Dohme Drug List
Given below is the complete list of Merck Sharp Dohme's drugs and the patents protecting them.
1. Belsomra
Belsomra is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10098892 | Solid dosage formulations of an orexin receptor antagonist |
29 May, 2033
(8 years from now)
| Active |
| US11980623 | Solid dosage formulations of an orexin receptor antagonist |
29 May, 2033
(8 years from now)
| Active |
| US7951797 | Substituted diazepan orexin receptor antagonists |
20 Nov, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belsomra's drug page
2. Clarinex
Clarinex is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6514520
(Pediatric)
| Stabilized antihistamine syrup |
01 Dec, 2018
(6 years ago)
| Expired |
| US6514520 | Stabilized antihistamine syrup |
01 Jun, 2018
(6 years ago)
| Expired |
| US7211582
(Pediatric)
| Methods for treating urticaria using descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(9 years ago)
| Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine |
30 Dec, 2014
(10 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(10 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex's drug page
3. Crixivan
Crixivan is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6689761 | Combination therapy for HIV infection |
10 Feb, 2021
(4 years ago)
| Expired |
| US6645961 | Dry granulation formulation for an HIV protease inhibitor |
04 Mar, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crixivan's drug page
4. Dutrebis
Dutrebis is protected by 9 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7754731
(Pediatric)
| Potassium salt of an HIV integrase inhibitor |
11 Sep, 2029
(4 years from now)
| Active |
| US7754731 | Potassium salt of an HIV integrase inhibitor |
11 Mar, 2029
(3 years from now)
| Active |
| US7169780
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
03 Apr, 2024
(1 year, 1 month ago)
| Expired |
| US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
03 Oct, 2023
(1 year, 7 months ago)
| Expired |
| US7820660 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
25 Apr, 2023
(2 years ago)
| Expired |
| US7217713
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Apr, 2023
(2 years ago)
| Expired |
| US7435734
(Pediatric)
| N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Apr, 2023
(2 years ago)
| Expired |
| US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Oct, 2022
(2 years ago)
| Expired |
| US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
21 Oct, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dutrebis's drug page
5. Januvia
Januvia is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7326708
(Pediatric)
| Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 May, 2027
(2 years from now)
| Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
24 Nov, 2026
(1 year, 6 months from now)
| Active |
| US6699871
(Pediatric)
| Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(2 years ago)
| Expired |
| US7125873
(Pediatric)
| Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(2 years ago)
| Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(6 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(6 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(6 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Januvia's drug page
Explore Our Curated Drug Screens
6. Juvisync
Juvisync is protected by 11 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7326708
(Pediatric)
| Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
11 Oct, 2026
(1 year, 5 months from now)
| Active |
| US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
11 Apr, 2026
(11 months from now)
| Active |
| US6699871
(Pediatric)
| Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(2 years ago)
| Expired |
| US7125873
(Pediatric)
| Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jan, 2023
(2 years ago)
| Expired |
| US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
26 Jul, 2022
(2 years ago)
| Expired |
| US8168637 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes |
26 Jun, 2022
(2 years ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(6 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(6 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(6 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Juvisync's drug page
7. Noxafil
Noxafil is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(7 years from now)
| Active |
| US9023790 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
04 Jul, 2031
(6 years from now)
| Active |
| US9358297 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
24 Jun, 2031
(6 years from now)
| Active |
| US10117951 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US5661151 | Tetrahydrofuran antifungals |
19 Jul, 2019
(5 years ago)
| Expired |
| US5703079 | Tetrahydrofuran antifungals |
26 Aug, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Noxafil's drug page
8. Prevymis
Prevymis is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10603384 | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
28 Feb, 2033
(7 years from now)
| Active |
| USRE46791 | Substituted dihydroquinazolines |
18 Jan, 2029
(3 years from now)
| Active |
| US7196086 | Substituted dihydroquinazolines |
22 May, 2024
(11 months ago)
| Expired |
| US8513255 | Substituted dihydroquinazolines |
22 May, 2024
(11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevymis's drug page
9. Rebetol
Rebetol is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6172046
(Pediatric)
| Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
21 Mar, 2018
(7 years ago)
| Expired |
| US6472373
(Pediatric)
| Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
21 Mar, 2018
(7 years ago)
| Expired |
| US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
21 Sep, 2017
(7 years ago)
| Expired |
| US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
21 Sep, 2017
(7 years ago)
| Expired |
| US6177074
(Pediatric)
| Polyethylene glycol modified interferon therapy |
01 May, 2017
(8 years ago)
| Expired |
| US6461605
(Pediatric)
| Continuous low-dose cytokine infusion therapy |
01 May, 2017
(8 years ago)
| Expired |
| US6524570
(Pediatric)
| Polyethylene glycol modified interferon therapy |
01 May, 2017
(8 years ago)
| Expired |
| US6177074 | Polyethylene glycol modified interferon therapy |
01 Nov, 2016
(8 years ago)
| Expired |
| US6461605 | Continuous low-dose cytokine infusion therapy |
01 Nov, 2016
(8 years ago)
| Expired |
| US6524570 | Polyethylene glycol modified interferon therapy |
01 Nov, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rebetol's drug page
10. Temodar
Temodar is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6987108 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
08 Sep, 2023
(1 year, 8 months ago)
| Expired |
| US7786118 | Pharmaceutical formulations of antineoplastic agents |
21 Feb, 2023
(2 years ago)
| Expired |
| US8623868 | Processes of making and using pharmaceutical formulations of antineoplastic agents |
21 Feb, 2023
(2 years ago)
| Expired |
| US5260291
(Pediatric)
| Tetrazine derivatives |
11 Feb, 2014
(11 years ago)
| Expired |
| US5260291 | Tetrazine derivatives |
11 Aug, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Temodar's drug page
11. Victrelis
Victrelis is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7772178 | Pharmaceutical formulations and methods of treatment using the same |
11 Nov, 2027
(2 years from now)
| Active |
| US8119602 | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
17 Mar, 2027
(1 year, 10 months from now)
| Active |
| USRE43298 | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
22 Dec, 2024
(4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Victrelis's drug page
12. Welireg
Welireg is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9908845 | Aryl ethers and uses thereof |
05 Sep, 2034
(9 years from now)
| Active |
| US9969689 | Aryl ethers and uses thereof |
05 Sep, 2034
(9 years from now)
| Active |
| USRE49948 | Aryl ethers and uses thereof |
05 Sep, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Welireg's drug page